PMID:21229552

Ghadersohi, A, Sharma, S, Zhang, S, Azrak, RG, Wilding, GE, Manjili, MH and Li, F (2011) Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.Prostate

Abstract

BACKGROUND: Reduced expression of prostate-derived Ets transcription factor (PDEF) leads to morphologic change as well as increased migration and invasiveness of prostate cancer cells. However, the clinical relevance of PDEF expression and its relationship to anti-apoptotic protein survivin is yet to be determined. METHODS: Tissue microarrays of 73 prostate carcinomas and their adjacent benign prostate tissue, as well as 50 benign prostates were evaluated for PDEF expression by immunohistochemistry. Results were confirmed in available tumor tissues using Western blot and RT-PCR. Expression of survivin in prostate carcinoma and benign tissues were determined using Western blot. Results and correlation with clinical data were statistically analyzed. RESULTS: Patients' specimens with low Gleason scores (GS < 5) expressed higher levels of PDEF protein and lower levels of survivin protein when compared with moderate-to-high GS tumors (GS > 6). Patients with PDEF-positive tumor survived significantly longer (P < 0.0001) than patients with PDEF-negative tumor, and the 8-year survival rate was 94% and 40%, respectively. PDEF expression was detected at the highest levels in benign tissues and was down-regulated or lost in 30 recently diagnosed prostate carcinomas. Re-expression of PDEF in prostate cancer cells inhibited survivin expression. Treatment of prostate cancer cells with methylseleninic acid resulted in restoration of PDEF expression, down-regulation of survivin, and inhibition of tumor cell growth when compared with untreated controls (P < 0.05). CONCLUSIONS: These studies demonstrated an inverse correlation between PDEF and survivin expression, and that up-regulation of PDEF was associated with a favorable prognosis in patients with clinically localized prostate cancer. Prostate © 2010 Wiley-Liss, Inc.

Links

PubMed Online version:10.1002/pros.21333

Annotations

Gene product	Qualifier	GO Term	Evidence Code	with/from	Aspect	Extension	Notes	Status
HUMAN:SPDEF		GO:0060770: negative regulation of epithelial cell proliferation involved in prostate gland development	ECO:0000314:		P		Fig 1:Western blot and one step RT-PCR showing expression of PDEF in normal and prostate lesions and cell lines.	complete
HUMAN:SPDEF		GO:0043065: positive regulation of apoptosis	ECO:0000314:		P		Fig 3: Immunohistochemisty staining is used to show the reducing levels of PDEF, the later stages of cancer. Confirming that PDEF has a role in prostate cancer development.	complete
HUMAN:SPDEF		GO:0008634: negative regulation of survival gene product expression	ECO:0000314:		P		Figure 7: Induction of apoptosis using MSeA causes an upregulation of PDEF and a down regulation of survivin.	complete
HUMAN:A2SUH6		GO:0060769: positive regulation of epithelial cell proliferation involved in prostate gland development	ECO:0000314:		P		Fig 1:Western blot and one step RT-PCR showing expression of survivin in normal and prostate lesions and cell lines. (There is only one surivivin human protein available on QuickGo. I dont know if it's the right one, as it is unreviewed and it doesnt mention its anti-apoptotic properties.)	complete
HUMAN:A2SUH6		GO:0006916: anti-apoptosis	ECO:0000314:		P		Figure 7: Confirms that the survivin protein is anti-apoptotic.	complete

References

See Help:References for how to manage references in GONUTS.